Updates are available Correction dated 2023-03-17
Click to view Correction: https://doi.org/10.1038/s41591-023-02309-4
-
Authors
Soliman, Hatem https://orcid.org/0000-0001-6644-2264
Hogue, Deanna https://orcid.org/0000-0002-0991-3338
Han, Hyo
Mooney, Blaise https://orcid.org/0000-0003-1030-5054
Costa, Ricardo
Lee, Marie C. https://orcid.org/0000-0002-1756-7279
Niell, Bethany
Williams, Angela
Chau, Alec
Falcon, Shannon
Soyano, Aixa
Armaghani, Avan
Khakpour, Nazanin
Weinfurtner, Robert J. https://orcid.org/0000-0002-4245-8744
Hoover, Susan
Kiluk, John
Laronga, Christine
Rosa, Marilin
Khong, Hung
Czerniecki, Brian
- License Information
-
More Information
Article History
Received: 30 April 2022
Accepted: 6 January 2023
First Online: 9 February 2023
Competing interests
: Funding for the trial was provided by Amgen. H.S. has received consulting fees from AstraZeneca, Novartis, Seattle Genetics, PUMA, Sanofi and Eisai; licensing fees for intellectual property from Celyad Oncology; and institutional research funding from Amgen. H.K. has sat on the scientific advisory board for Celcuity; holds equities in Agenus, TG Therapeutics, Vexart, Lipocine, Mustang Bio, MEI Pharma and Tiziana Life Sciences; and has received institutional research support from AstraZeneca. M.C.L. has received research funding from Elucent Medical. S.H. has sat on the advisory board of Devicor/Mammotome. H.H. has received fees for advisory and speaker bureau activities from Lilly, Novartis and Immunomedics. B.C. has received advisory fees from Merit Oncology and has intellectual property rights with Immunorestoration. M.R. has received speaker fees from Roche. A.W., D.H., S.F., A.S., N.K., J.K., C.L., A.A., R.C., R.J.W., B.M. and A.C. declare no competing interests.
